Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1351 - Effects of smoking habit in NSCLC with KRAS mutation in pathological stage I


20 Dec 2015


Poster presentation 2


Hiroaki Kuroda


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


H. Kuroda1, K. Seto2, T. Yoshida3, T. Mizuno3, N. Sakakura3, T. Hida3, Y. Yatabe4, Y. Sakao5

Author affiliations

  • 1 Thoracic Surgery, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2 Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya/JP
  • 3 Department Of Thoracic Oncology, Aichi Cancer Center Hospital, 464–8681 - Nagoya/JP
  • 4 Department Of Pathology And Molecular Diagnosis, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 5 Department Of Thracic Surgery, Aichi Cancer Center Hospital, Nagoya/JP


Abstract 1351


KRAS mutation plays important roles in the pathobiology of NSCLC and is well known to the resistance of EGFR inhibitors. KRAS mutation is strongly associated with smoking habit, but the non to light smoker having KRAS mutation rarely exist.


We conducted a retrospective study of 104 patients diagnosed as KRAS mutation compared to 217 patients with the diagnosis as Wild type in pathological stage I. The proportion of non to light smoker {smoking index (SI): 0 to 400} were 37.5 (39/104) in the patients with KRAS mutation.


KRAS with more than 400 in SI showed a shorter survival than KRAS with non to light smoker or Wild type (p = 0.03 and p < 0.01). The maximum tumor size and mediastinal size on preoperative CT was equivalent between the difference of smoking habit in KRAS mutation. Preoperative CEA was 4.56-fold higher in KRAS with more than 400 in SI than those with non to light (p < 0.01).


Our results suggested that KRAS mutation showed the poor prognosis in spite of stage I NSCLC. However, non to light smoker might have the possibility of contribution to improve prognosis among them.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings